Heron Therapeutics (NASDAQ:HRTX) Lifted to Hold at StockNews.com

Heron Therapeutics (NASDAQ:HRTX) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Thursday.

Separately, Needham & Company LLC dropped their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday.

Heron Therapeutics Stock Performance

NASDAQ HRTX opened at $1.09 on Thursday. The stock has a market capitalization of $163.58 million, a price-to-earnings ratio of -1.14 and a beta of 1.12. The stock’s 50 day moving average price is $0.86 and its two-hundred day moving average price is $1.26. Heron Therapeutics has a 52 week low of $0.50 and a 52 week high of $3.41.

Insider Buying and Selling

In other Heron Therapeutics news, CEO Craig A. Collard bought 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were acquired at an average cost of $0.92 per share, with a total value of $138,000.00. Following the acquisition, the chief executive officer now owns 186,496 shares of the company’s stock, valued at $171,576.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Craig A. Collard acquired 150,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were purchased at an average cost of $0.92 per share, with a total value of $138,000.00. Following the acquisition, the chief executive officer now directly owns 186,496 shares in the company, valued at approximately $171,576.32. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Ira Duarte acquired 85,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was purchased at an average cost of $0.89 per share, for a total transaction of $75,650.00. Following the completion of the acquisition, the chief financial officer now owns 85,000 shares in the company, valued at $75,650. The disclosure for this purchase can be found here. 6.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sei Investments Co. acquired a new stake in shares of Heron Therapeutics during the 1st quarter worth $27,000. State of Wyoming acquired a new stake in shares of Heron Therapeutics during the 2nd quarter worth $28,000. SG Americas Securities LLC acquired a new stake in shares of Heron Therapeutics during the 3rd quarter worth $31,000. Citigroup Inc. grew its holdings in shares of Heron Therapeutics by 195.6% during the 2nd quarter. Citigroup Inc. now owns 30,845 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 20,412 shares in the last quarter. Finally, Point72 Middle East FZE acquired a new stake in shares of Heron Therapeutics during the 4th quarter worth $37,000. 81.77% of the stock is owned by institutional investors and hedge funds.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.